These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11188778)

  • 1. The Austrian Immunoglobulin in MS (AIMS) study: final analysis.
    Strasser-Fuchs S; Fazekas F; Deisenhammer F; Nahler G; Mamoli B
    Mult Scler; 2000 Oct; 6 Suppl 2():S9-13. PubMed ID: 11188778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
    Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y
    Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect on MRI of gammaglobulin treatment in relapsing multiple sclerosis.
    Sørensen PS
    Mult Scler; 2000 Oct; 6 Suppl 2():S14-7. PubMed ID: 11188772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.
    Sørensen PS
    Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Mult Scler; 1997 Apr; 3(2):137-41. PubMed ID: 9291168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Lancet; 1997 Mar; 349(9052):589-93. PubMed ID: 9057729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravenous immunoglobulins for relapsing-remitting multiple sclerosis after failure of treatment with other immuno-modulators].
    Lebrun C; Ghetau G; Bourg V; Chanalet S; Dumas S; Chatel M
    Rev Neurol (Paris); 2003 Jul; 159(6-7 Pt 1):648-51. PubMed ID: 12910072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G; Filippi M; Wolinsky JS
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins--interim results on drug safety of an ongoing study. IVIG study group.
    Poehlau D
    Mult Scler; 2000 Oct; 6 Suppl 2():S21-3. PubMed ID: 11188774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
    Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin in MS: promise or failure?
    Fazekas F; Strasser-Fuchs S; Hommes OR
    J Neurol Sci; 2007 Aug; 259(1-2):61-6. PubMed ID: 17449063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.